translation 17 ket. The short answer was that products and services were being created that the market did not value.The NSF grantees were developing products, tools, and/or solutions without learning who their potential customers might be, or how they might best be adopted in the real world by users. To address this issue, the NSF created the Innovation-Corps (I-Corps) program to get researchers out of their labs to discover more about potential customers and potential uses for their technology. JHU fully embraced the I-Corps program and
now serves as a regional hub for the nation-
al program. The regional program is based on the same principals as the national program, but it is shorter in length. The goal of this shorter course is to validate a specific problem or need and to determine what products or services could address this need, while longer courses include further steps to develop a business model around solving that specific problem. The regional I-Corps program is one of the first programs we encourage our students and faculty to participate in once they start thinking about commercializing their research.
Does My Invention Solve Real World Problems? had been achieved and daunted by the path ahead towards clinical development and implementation, which is why I enrolled in the JHTV I-Corps course.
By Chris Yankaskas, PhD After publishing a paper on the development of a microfluidic assay to predict breast cancer patients’ risk of developing metastasis and to identify effective therapeutics, I asked, “what next?” (Go to page 10 to learn more about this research). Having spent years working on a translational project, I was excited by what
The course’s main goal is to ensure that the problem of interest is real and solvable. Elizabeth Good Mazhari was my instructor and has a long resume of working with and for tech startup companies and ventures, and is a National Faculty I-Corps Instructor for NSF and NIH. To obtain wide and objective views on my problem of interest, she covered how to conduct interviews to test hypotheses about market problems and conditions with the people I think are experiencing the problem—in my case, chiefly oncologists. I admittedly have not spent a lot of time talking to clinicians who experience the problem that my research works to solve, and did
